Clearmind CEO Joins Federal Psychedelic Medicine Policy Summit
Event summary
- Clearmind Medicine CEO Dr. Adi Zuloff-Shani attended the invite-only Federal Policy Summit on Psychedelic Medicine in Washington, D.C., on May 14, 2026.
- The summit convened U.S. Senate and House members alongside global psychedelic biopharma leaders, researchers, and clinicians from institutions like Johns Hopkins and Yale.
- Clearmind is advancing its non-hallucinogenic psychedelic candidate with Phase IIa clinical trials underway at leading sites including Johns Hopkins and Yale.
The big picture
Clearmind’s CEO joining this high-profile policy summit underscores the growing intersection of biopharma innovation and regulatory governance in the psychedelic medicine space. The event highlights bipartisan efforts to bridge gaps between research, policy, and patient care, which could significantly impact companies developing novel therapeutics. With Phase IIa trials underway at top institutions, Clearmind is positioning itself at the forefront of this emerging sector.
What we're watching
- Regulatory Alignment
- How Clearmind's participation in the summit will influence regulatory harmonization between legislators and biopharma leaders.
- Clinical Progress
- The pace at which Phase IIa trials for Clearmind’s non-hallucinogenic psychedelic candidate advance, particularly with high-profile institutions like Johns Hopkins and Yale involved.
- Policy Impact
- Whether the bipartisan working group can accelerate federal support for psychedelic-derived therapies, potentially benefiting companies like Clearmind.